Lazard Asset Management
PACB icon

Lazard Asset Management’s Pacific Biosciences PACB Stock Holding History

Lazard Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,549
Closed -$29K – 2403
2023
Q3 		$29K Hold
3,549
– – ﹤0.01% 2038
2023
Q2 		$47K Buy
3,549
+57
+2% +$693 ﹤0.01% 1853
2023
Q1 		$40K Buy
+3,492
New +$34.7K ﹤0.01% 1863
2020
Q4 		– Sell
-7,915
Closed -$78K – 1943
2020
Q3 		$78K Sell
7,915
-2,232
-22% -$12.8K ﹤0.01% 1061
2020
Q2 		$35K Buy
10,147
+3,197
+46% +$10.9K ﹤0.01% 1321
2020
Q1 		$21K Buy
+6,950
New +$28.5K ﹤0.01% 1429

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Lazard Asset Management's PACB Position: Q4 2023 in Review

Lazard Asset Management sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 3,549 shares — an estimated $29K sold.

Lazard Asset Management first reported a position in PACB in Q1 2020 and held it in 6 quarters. The position peaked at $78K in Q3 2020. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

  • Lazard Asset Management reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
  • Lazard Asset Management sold 3,549 Pacific Biosciences shares in Q4 2023, an estimated $29K.
  • Lazard Asset Management first reported a position in Pacific Biosciences in Q1 2020 and held it in 6 quarters.
  • Lazard Asset Management's Pacific Biosciences position peaked at $78K in Q3 2020.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Lazard Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.